Why the study?
The clinical utility of doxorubicin is limited by cardiomyopathy, necessitating the identification of effective treatments and cardioprotective strategies against doxorubicin-induced cardiomyopathy.
Do current and emerging pharmacological and natural treatments mitigate doxorubicin-induced cardiomyopathy in human and animal models?
Do current and emerging pharmacological and natural treatments mitigate doxorubicin-induced cardiomyopathy in human and animal models?
A variety of pharmacological and natural agents show promise in mitigating doxorubicin-induced cardiomyopathy in preclinical models, highlighting the need for further clinical trials in patients with preexisting cancer.
Answers are grounded in this paper and cite their sources.
I need the paper’s actual verdict and evidence level before writing the implication. Searching Cureus for the doxorubicin cardiomyopathy review.Opening the Cureus review to extract the authors’ verdict and conclusions.The article pages didn’t return the full text. Trying the PDF and Europe PMC.Opening the PDF for the review’s conclusions and key finding.Pulling the conclusions section to lock the
Doxorubicin (DOX) is an anthracycline antibiotic used to treat many cancers, including breast cancer, leukemia, and Hodgkin's lymphoma. Positive aspects of DOX use are limited by the cardiomyopathy that it may cause. For this reason, it is crucial to uncover effective treatments against DOX-induced cardiomyopathy (DIC). Oxidative stress plays a pivotal role in DIC, and this understanding has helped guide potential treatments for DIC. The purpose of this study was to review and describe current and emerging treatments for DIC and their potential cardioprotective effects against DIC. The goals were to: (1) provide a single-source report to aid clinicians in exploring different treatment plans that are personalized for their patients and (2) stimulate researchers to consider evaluating promising and emerging treatment modalities. Evolving understanding of DIC pathophysiology remains fundamental in elucidating the course for future medical therapies. The main conclusion of this study was that the use of existing pharmaceutical agents might represent a possible approach towards mitigating DIC with more extensive clinical data. A limitation of all reviewed studies was that none included an experimental model in which DOX was used to treat animals with preexisting cancer. This limitation fails to identify the impacts that cancer may play in DIC pathophysiology and the potential mitigating effects of DIC treatments. Future research should consider this limitation with appropriately revised protocols.
No takes yet. Share an insight, caveat, or question.
Kabir et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: